7 “Ioannis Gounaris” profil | LinkedIn
Ioannis Gounaris's research works | Novartis, Basel and other places
Simple blood test could quickly predict how ovarian cancer patients are likely to respond to chemotherapy treatment | Obs Gynae & Midwifery News – Incorporating Women's Health
Ioannis Gounaris's research works | Novartis, Basel and other places
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study | PLOS Medicine
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. - Abstract - Europe PMC
Our Publications
Trastuzumab-associated cardiac events in the Persephone trial | British Journal of Cancer
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
Natasha LeGresley (@tashlegr) / Twitter
De-grading Petition - Disabled Students' Campaign
7 perfiles de «Ioannis Gounaris» | LinkedIn
Ioannis Gounaris's research works | Novartis, Basel and other places
Application of ARID1A to murine formalin-fixed... | F1000Research
Trabectedin for advanced soft tissue sarcomas: a single institution experience
Ioannis Gounaris's research works | Novartis, Basel and other places
Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
400+ "Gounaris" profiles | LinkedIn
A Bumpy Virtual #ASCO20; Returning to Chicago in 2021?
Ioannis Gounaris - Executive Medical Director - Merck Group | LinkedIn
Ioannis Gounaris's research works | Novartis, Basel and other places
